When Elon Musk’s Department of Government Efficiency came knocking at the SEC’s door in early 2025, agency employees had questions. Specifically, the kind of questions you ask when someone wants the ...

We all know how maddening an unreachable itch can be. Galapagos sharks have found a creative solution to this problem: manta rays, apparently, make excellent snout scratchers.At three different dive ...

Billions of dollars are being poured into a niche corner of the private credit world to build data centers despite jitters on Wall Street about the lenders' concentration in artificial intelligence.

Sen. Elizabeth Warren, a Democrat from Massachusetts, is expressing her concerns on this big day for SpaceX, saying in a statement today that the Trump administration's Securities and Exchange ...

The SEC just made a big move on financial data. The Commission rolled out joint technical standards under the Financial Data Transparency Act of 2022, a law that’s been sitting on the shelf waiting ...

The Securities and Exchange Commission on Monday announced that it had established joint data standards as required under the Financial Data Transparency Act, and those standards aren't "as ...

Should researchers still be posting their data openly online? It’s a question being debated by some researchers now that bots are routinely mining open-access databases and scientific publications to ...

sec-edgar-mcp is sister to schwab-marketdata-mcp. Where Schwab provides prices and quotes, SEC EDGAR provides the corporate-action / disclosure backbone (10-K / 10-Q / 8-K / Form 4 insider trades, S-1 ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. CB Financial Services cybersecurity disclosure reveals shadow AI risk. A harsh lesson about ...

ORTEX is a financial data provider specializing in short interest data and securities lending analytics. Its datasets combine exchange-reported data with securities lending intelligence, using ...

The securities action alleges that throughout a multi-year class period, Aldeyra's leadership was aware, or recklessly disregarded, that reproxalap's clinical trial record did not support the ...

This was a new position for the fund and represented 3.64% of its reportable 13F assets under management at quarter-end. Top holdings after the filing: NYSE:U: $57.98 million (11.8% of AUM) ...